Table 5.
TKI Agent | Average QT prolongation (ms) | Increase in QTc >60ms (%) | QTc >500ms (%) | Torsades de pointes (%) |
---|---|---|---|---|
Axitinib | <10 | N/a | N/a | N/a |
Cabozantinib | 10-15 | N/a | N/a | N/a |
Pazopanib | N/a | N/a | 2 | <0.3 |
Sorafenib | 8-13 | N/a | N/a | N/a |
Sunitinib | 9.6-15.4 | 1-4 | 0.5 | <0.1 |
Vandetanib | 36 | 12-15 | 4.3-8 | Described, % N/a |